Dental implant maker Nobel Biocare's second-quarter revenues for 2013 rose 2.3% as its European business grew for the first time in six years.
For the quarter (end-March 31), the company reported revenues of $289.4 million euros ($385.6 million U.S.), down 2.4% from $296.5 million euros ($395 million) from the same period last year. Net profit for the quarter dropped to 8 million euros ($10.6 million), compared with profit of 13.7 million euros ($18.25 million) for the same quarter a year ago.
Nobel is trying to regain market share lost to bigger rival Straumann Holding and is investing in product development and the expansion of its value implant business, Alpha-Bio Tec.
"We see clear signs that our investments in innovation are accelerating revenue growth. Our implant systems grew midsingle digits in Q2 driven by NobelActive, NobelActive 3.0, and the new Nobel-Replace line," said CEO Richard Laube.
